Novo Nordisk To 'Double Obesity Drug Sales by 2025'

Danish Group Says Year Off To ‘Good Start’

 
• By Sten Stovall
Group Plans Phase IIIa Oral Semaglutide Obesity Trial Dosed At 50mg • Source: Alamy

More from Earnings

More from Business